SER (Serina Therapeutics) Enterprise Value-to-Revenue Multiple

serinatherapeutics.com (SER) - corporate logo

Serina Therapeutics, Inc. (SER) leverages its proprietary polymer system to diversify B2B revenue streams by optimizing the delivery of Parkinson's disease treatments. The price-to-sales ratio confirms this efficiency, with 132083.33 serving as the current parameter value. Innovations in compound development establish a foundation for sustained monetization, while the launch of the POZ testing program following the asset merger solidifies the long-term growth strategy.

SER Serina Therapeutics: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

Serina Pharma - analytical breakdowns and key metrics (SER)

- stock value and consensus price forecast:
- business market valuation indicators:
- cash and cash flow indicators:
Initial company analysis:Serina Therapeutics, Inc., SER
Product sample of Serina

This indicator compares the total business value to sales volume, excluding the impact of debt load to identify the actual market premium paid for operating results. For Serina Therapeutics, Inc. (SER), whose revenues depend on the outcome of clinical tests for drug delivery systems, the Enterprise Value to revenue ratio serves as a marker of speculative market expectations regarding the future commercialization of polymers.